Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFIRI + ramucirumab
- Development stage
- Phase 3
- Lead developer
- Eli Lilly
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FOLFIRI + ramucirumab is a combination regimen used primarily as a second-line treatment for metastatic colorectal cancer (mCRC) and gastroesophageal adenocarcinoma. The regimen consists of the chemotherapy combination FOLFIRI—comprising folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan—administered together with ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR-2). Ramucirumab inhibits angiogenesis by blocking VEGFR-2 signaling, thereby reducing tumor blood supply. The chemotherapeutic agents in FOLFIRI work synergistically to disrupt DNA synthesis and cell division in rapidly proliferating cancer cells. This combination has demonstrated efficacy in prolonging progression-free survival and overall survival in patients whose disease has progressed after first-line therapy[1][3][4].
- Other names
- FOLFIRI plus ramucirumabFOLFIRI + RAMRAM + FOLFIRI
02
Targets
TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on FOLFIRI + ramucirumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFIRI + ramucirumab.